Richard R. Furman, MD
The median overall survival (OS) for patients with chronic lymphocytic leukemia (CLL) has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis, said Richard Furman, MD, director of the Weill Cornell Medicine CLL Research Center, at the 36th Annual CFS®
While single-agent ibrutinib is sufficient for many patients, those with Richter’s transformation, del17p, complex karyotypes, or age below 65 years, may be ideal for an experimental combination strategy. For these patients, Furman encouraged enrollment in a clinical trial.
- O’Brien SM, Furman RR, Coutre SE, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Presented at: 58th American Society of Hematology Annual Meeting; San Diego, CA; December 3-6, 2016. Abstract 233.
- BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282.
- Rossie D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401. doi: 10.1182/blood-2010-09-302174.
- Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. BJH. 2012;158(3):426-9. Br J Haematol. doi: 10.1111/j.1365-2141.2012.09155.x
... to read the full story